Mer­ri­mack Phar­ma’s stock plunges (again) on its lat­est can­cer drug tri­al flop

Mer­ri­mack Phar­ma­ceu­ti­cals $MACK has an­oth­er los­er on its hands.

The drug MM-121 (serib­an­tum­ab) added to do­c­etax­el did not do any bet­ter than do­c­etax­el alone in …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER